Trial · NCT00927082
Adverse events104
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 104
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper respiratory tract infection | Infections and infestations | PEG-IFN 90mcg 24 Wks | 5 | 93 | |
| other | Upper respiratory tract infection | Infections and infestations | PEG-IFN 180mcg 24 Wks | 6 | 89 | |
| other | Upper respiratory tract infection | Infections and infestations | PEG-IFN 90mcg 48 Wks | 4 | 106 | |
| other | Upper respiratory tract infection | Infections and infestations | PEG-IFN 180mcg 48 Wks | 7 | 95 | |
| other | Alanine aminotransferase increased | Investigations | PEG-IFN 90mcg 24 Wks | 3 | 93 | |
| other | Alanine aminotransferase increased | Investigations | PEG-IFN 180mcg 24 Wks | 2 | 89 | |
| other | Alanine aminotransferase increased | Investigations | PEG-IFN 90mcg 48 Wks | 4 | 106 | |
| other | Alanine aminotransferase increased | Investigations | PEG-IFN 180mcg 48 Wks | 5 | 95 | |
| serious | Hepatocellular carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | PEG-IFN 90mcg 24 Wks | 1 | 93 | |
| serious | Hepatocellular carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | PEG-IFN 180mcg 24 Wks | 0 | 89 | |
| serious | Hepatocellular carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | PEG-IFN 90mcg 48 Wks | 3 | 106 | |
| serious | Hepatocellular carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | PEG-IFN 180mcg 48 Wks | 0 | 95 | |
| serious | Gastrointestinal carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | PEG-IFN 90mcg 24 Wks | 0 | 93 | |
| serious | Gastrointestinal carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | PEG-IFN 180mcg 24 Wks | 0 | 89 | |
| serious | Gastrointestinal carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | PEG-IFN 90mcg 48 Wks | 0 | 106 | |
| serious | Gastrointestinal carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | PEG-IFN 180mcg 48 Wks | 1 | 95 | |
| serious | Appendicitis | Infections and infestations | PEG-IFN 90mcg 24 Wks | 0 | 93 | |
| serious | Appendicitis | Infections and infestations | PEG-IFN 180mcg 24 Wks | 0 | 89 | |
| serious | Appendicitis | Infections and infestations | PEG-IFN 90mcg 48 Wks | 1 | 106 | |
| serious | Appendicitis | Infections and infestations | PEG-IFN 180mcg 48 Wks | 0 | 95 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00927082/events